AREXVY

BIOLOGICAL2 trials

Sponsors

Clover Biopharmaceuticals AUS Pty, Clover Biopharmaceuticals USA, LLC

Conditions

RSV InfectionRespiratory Syncytial Virus Vaccination

Phase 1

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

CompletedNCT06194318

Clover Biopharmaceuticals AUS PtyRespiratory Syncytial Virus Vaccination

Start: 2023-12-13End: 2025-05-07Updated: 2025-06-06

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

RecruitingNCT06843317

Clover Biopharmaceuticals USA, LLCRSV Infection

Start: 2025-03-21End: 2026-06-03Target: 160Updated: 2025-05-14